EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies

Henry Daniell iD, Geetanjali Wakade, Smruti K Nair iD, Rahul Singh, Steven A Emanuel, Barry Brock, Kenneth B Margulies iD

Pharmaceutics · 25.12.2024 · 17 (1) · 12

DOI: 10.3390/pharmaceutics17010012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 25.12.2024. Verfasst von Henry Daniell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: For several decades, protein drugs (biologics) made in cell cultures have been delivered as sterile injections, decreasing their affordability and patient preference. Angiotensin Converting Enzyme 2 (ACE2) gum is the first engineered human blood protein expressed in plant cells approved by the FDA without the need for purification and is a cold-chain and noninvasive drug delivery. This biologic is currently being evaluated in human clinical studies to debulk SARS-CoV-2 in the oral cavity to reduce coronavirus infection/transmission (NCT 0543318).

Methods

Chemistry, manufacturing, and control (CMC) studies for the ACE2/Ang(1–7) drug substances (DSs) and ACE2 gum drug product (DP) were conducted following USP guidelines. GLP-compliant toxicology studies were conducted on Sprague Dawley rats (n = 120; 15/sex/group) in four groups—placebo, low (1.6/1.0 mg), medium (3.2/2.0 mg), and high (8.3/5.0 mg) doses IP/kg/day. Oral gavage was performed twice daily for 14 days (the dosing phase) followed by the recovery phase (35 days). Plasma samples (n = 216) were analyzed for the product Ang(1–7) by ELISA.

Results

The ACE2 protein was stable in the gum for at least up to 78 weeks. The toxicology study revealed the dose-related drug delivery to the plasma and increases in the AUC (56.6%) and Cmax (52.9%) after 28 high-dose gavages (95% C.I.), although this quantitation excludes exogenously delivered membrane-associated ACE2/Ang(1–7). Vital biomarkers and organs were not adversely affected despite the 10-fold higher absorption in the tissues, demonstrating the safety for the first in-human clinical trials of ACE2/Ang(1–7). The NOAEL observed in the rats was 2.5–7.5-fold higher than that of the anticipated efficacious therapeutic dose in humans for the treatment of cardiopulmonary disorders, and it was 314-fold higher than the NOAEL for topical delivery via chewing gum.

Conclusions

This report lays the foundation for the regulatory process approval for noninvasive and affordable human biologic drugs bioencapsulated in plant cells.

Schlagwörter

Stichwörter der Autor:innen

Angiotensin Converting Enzyme 2CMCbiologicoral drug deliverytoxicology

Autor:innen und Institutionen

  • Department of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Henry Daniell, Smruti K Nair, Kenneth B Margulies

Förderung

  • NIDCR NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • NIH
  • Commonwealth of Pennsylvania, Department of Community and Economic Development grant

Zitieren

APA

Daniell, H., Wakade, G., Nair, S. K., Singh, R., Emanuel, S. A., Brock, B., & Margulies, K. B. (2024). Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies. Pharmaceutics, 17(1), 12. https://doi.org/10.3390/pharmaceutics17010012

Vancouver

Daniell H, Wakade G, Nair SK, Singh R, Emanuel SA, Brock B, et al. Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies. Pharmaceutics. 2024;17(1):12. doi:10.3390/pharmaceutics17010012

BibTeX
@article{Daniell2024,
  author = {Daniell, Henry and Wakade, Geetanjali and Nair, Smruti K and Singh, Rahul and Emanuel, Steven A and Brock, Barry and Margulies, Kenneth B},
  title = {Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {17},
  number = {1},
  pages = {12},
  doi = {10.3390/pharmaceutics17010012}
}
Kostenlos starten →